Lijuan Wang1,2, Xizhi Luo1, Chao Cheng3,4, Christopher I Amos3,4, Guoshuai Cai5, Feifei Xiao6. 1. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, 29208, USA. 2. Department of Epidemiology and Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. 3. Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. 4. Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030, USA. 5. Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, 29208, USA. 6. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, 29208, USA. xiaof@mailbox.sc.edu.
Abstract
BACKGROUND: Lung adenocarcinoma (LUAD) has become the most frequent histologic type of lung cancer in the past several decades. Recent successes with immune checkpoint blockade therapy have demonstrated that the manipulation of the immune system is a very potent treatment for LUAD. This study aims to explore the role of immune-related genes in the development of LUAD and establish a signature that can predict overall survival for LUAD patients. METHODS: To identify the differential expression genes (DEGs) between normal and tumor tissues, we developed an analysis strategy to combine an independent-sample design and a paired-sample design using RNA-seq transcriptomic profiling data of The Cancer Genome Atlas LUAD samples. Further, we selected prognostic markers from DEGs and evaluated their prognostic value in a prediction model. RESULTS: We identified and validated PD1, PDL1 and CTLA4 genes as prognostic markers, which are well-known immune checkpoints, and revealed two new potential prognostic immune checkpoints for LUAD, HHLA2 (logFC = 2.55, FDR = 1.89 × 10-6) and VTCN1 (logFC = -2.86, FDR = 1.72 × 10-11). Furthermore, we identified an 18-gene LUAD prognostic biomarker panel and observed that the classified high-risk group presented a significantly shorter overall survival time (HR = 3.57, p value = 4.07 × 10-10). The prediction model was validated in five independent high-throughput gene expression datasets. CONCLUSIONS: The identified DEG features may serve as potential biomarkers for prognosis prediction of LUAD patients and immunotherapy. Based on that assumption, we identified a gene expression-based immune signature for lung adenocarcinoma prognosis.
BACKGROUND:Lung adenocarcinoma (LUAD) has become the most frequent histologic type of lung cancer in the past several decades. Recent successes with immune checkpoint blockade therapy have demonstrated that the manipulation of the immune system is a very potent treatment for LUAD. This study aims to explore the role of immune-related genes in the development of LUAD and establish a signature that can predict overall survival for LUAD patients. METHODS: To identify the differential expression genes (DEGs) between normal and tumor tissues, we developed an analysis strategy to combine an independent-sample design and a paired-sample design using RNA-seq transcriptomic profiling data of The Cancer Genome Atlas LUAD samples. Further, we selected prognostic markers from DEGs and evaluated their prognostic value in a prediction model. RESULTS: We identified and validated PD1, PDL1 and CTLA4 genes as prognostic markers, which are well-known immune checkpoints, and revealed two new potential prognostic immune checkpoints for LUAD, HHLA2 (logFC = 2.55, FDR = 1.89 × 10-6) and VTCN1 (logFC = -2.86, FDR = 1.72 × 10-11). Furthermore, we identified an 18-gene LUAD prognostic biomarker panel and observed that the classified high-risk group presented a significantly shorter overall survival time (HR = 3.57, p value = 4.07 × 10-10). The prediction model was validated in five independent high-throughput gene expression datasets. CONCLUSIONS: The identified DEG features may serve as potential biomarkers for prognosis prediction of LUAD patients and immunotherapy. Based on that assumption, we identified a gene expression-based immune signature for lung adenocarcinoma prognosis.
Authors: Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam Journal: Lancet Oncol Date: 2015-02-20 Impact factor: 41.316
Authors: Vanda Téglási; Lilla Reiniger; Katalin Fábián; Orsolya Pipek; Irén Csala; Attila G Bagó; Péter Várallyai; Laura Vízkeleti; Lívia Rojkó; József Tímár; Balázs Döme; Zoltán Szállási; Charles Swanton; Judit Moldvay Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Ramon Andrade de Mello; Ana Flávia Veloso; Paulo Esrom Catarina; Sara Nadine; Georgios Antoniou Journal: Onco Targets Ther Date: 2016-12-16 Impact factor: 4.147
Authors: N Yamazaki; H Uhara; S Fukushima; H Uchi; N Shibagaki; Y Kiyohara; A Tsutsumida; K Namikawa; R Okuyama; Y Otsuka; T Tokudome Journal: Cancer Chemother Pharmacol Date: 2015-09-25 Impact factor: 3.333
Authors: Maya Hassane; Zahraa Rahal; Nareg Karaoghlanian; Jiexin Zhang; Ansam Sinjab; Justin W Wong; Wei Lu; Paul Scheet; J Jack Lee; Maria Gabriela Raso; Luisa M Solis; Junya Fujimoto; Hassan Chami; Alan L Shihadeh; Humam Kadara Journal: Cancer Prev Res (Phila) Date: 2022-07-05